April 2025 Manuscript "Small molecule BLVRB redox inhibitor promotes megakaryocytopoiesis and stress thrombopoiesis in vivo" is published by Nature Communications

​

August 2024 Blood Cell Technologies becomes a resident of JLABS@NYC

​

September 2024 Composition of matter patent finalized; International PCT filed to protect BLVRB inhibitors

 

September 2023 Composition of matter provisional patent filed to protect first-in-class BLVRB inhibitors with finalization anticipated September 2024

​

September 2023 BCT Receives SBIR Phase I Award “Development of a new class of BLVRB-targeted redox therapeutics in breast cancer”

​

October 2022 BCT receives NIH Technical and Business Assistance (TABA) funding to assist with Intellectual property protections

 

September 2021 BCT Receives SBIR Phase II $2.07M Award “Optimization of biliverdin IXβ reductase redox inhibitors as novel reagents for enhancing platelet production”

 

June 2020 BCT Receives SBIR Phase I Award “Detection of fetal platelets in maternal blood using platelet RNA biomarkers”

 

September 2017 BCT Receives SBIR Phase I Award “HLS Detection of RNA biomarkers in individual platelets”

 

July 2015 BCT receives SBIR Phase I Award “Development of a biliverdin IX Beta reductase redox inhibitor for enhanced platelet production”

July 2015 Blood Cell Technologies founded as a limited liability corporation (LLC)